Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191724
Status:
COMPLETED
Last Update Posted:
2009-06-24
First Post:
2005-09-12
Brief Title:
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa Activated Phase II Exploratory Study
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Drotrecogin Alfa Activated LY203638 Exploratory Safety Study Multi-Center Randomized Placebo-Controlled Dose Escalating Study Design Comparing a Standard Therapy Enoxaparin Sodium for Submassive Pulmonary Embolism to a Combined Therapy of Drotrecogin Alfa Activated Plus Enoxaparin Sodium
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An exploratory multicenter randomized placebo-controlled double blind dose escalation study comparing a standard therapy for submassive pulmonary embolism Enoxaparin sodium to a combined therapy of Drotrecogin alfa activated plus Enoxaparin sodium
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1K-MC-O014 | None | None | None |